-+ 0.00%
-+ 0.00%
-+ 0.00%

Angelini Ventures co-leads RougeTx USD 58 million Series A round

PUBT·10/06/2026 07:37:35
Listen to the news
Angelini Ventures co-leads RougeTx USD 58 million Series A round
  • Angelini Ventures co-led RougeTx’s USD 58 million Series A financing, backed by the European Investment Bank via the Aurea co-investment vehicle.
  • RougeTx is a preclinical biotech developing first-in-class, disease-modifying therapies to restore vascular integrity by targeting pericyte dysfunction.
  • Proceeds will advance lead program RTX-001 toward first-in-human trials for hereditary hemorrhagic telangiectasia, a rare inherited bleeding disorder.
  • The company’s periSCOPE platform is also being used to identify additional opportunities in diseases linked to vascular instability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelini Ventures SpA published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.